Phase 1/2 Trial of CAR-T Cell Immunotherapy in Metastatic, Mesothelin-Expressing Cancer
Researchers are evaluating whether CAR-T cell immunotherapy that targets mesothelin is safe and effective among patients with mesothelin-expressing tumors.
Title: Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes1
Principal Investigator: Steven A Rosenberg, MD, National Cancer Institute (NCI)
Description: For this open-label, single-group assignment phase 1/2 study (ClinicalTrials.gov Identifier: NCT01583686), researchers are evaluating whether chimeric antigen receptor (CAR)-T cell immunotherapy that targets mesothelin is safe and effective among patients with metastatic, mesothelin-expressing tumors.
Patients with mesothelioma or cervical, pancreatic, ovarian, or lung cancer will be enrolled to receive fludarabine, anti-mesothelin CAR-T cell therapy, cyclophosphamide, and aldesleukin. All patients will undergo leukapheresis prior to therapy; white blood cells will modified to target mesothelin.
The primary outcomes are safety and anti-tumor efficacy. The estimated number of enrolled patients is 136.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01583686.
Status: This study is open and recruiting patients as of April 27, 2018.
This study is sponsored by the NCI.
- Clinicaltrials.gov. CAR T cell receptor immunotherapy targeting mesothelin for patients with metastatic cancer. NCT01583686. https://clinicaltrials.gov/ct2/show/NCT01583686. Accessed April 27, 2018.